Compare Mesoblast Limited (MESO) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs M&T Bank Corporation — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while M&T Bank Corporation trades at $222.43 (market cap $31.28B). The key difference: M&T Bank Corporation is far larger — about 17.3× Mesoblast Limited's market cap, and M&T Bank Corporation pays a 2.77% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and M&T Bank Corporation for 100 Days on average.
| MESO | MTB | |
|---|---|---|
Market Cap | $1.81B | $31.28B |
Volume | 240,620 | 934,561 |
Sector | Health | Financials |
52-Week High | $20.96 | $254.09 |
52-Week Low | $13.19 | $178.63 |
Typical Hold Time | 14 Days | 100 Days |
Enterprise Value | $1.89B | $47.64B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
M&T Bank (MTB) trades at $217.56, down 0.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows solid fundamentals with a P/E of 11.47, net income margin of 30.85%, and consistent earnings beats in recent quarters. Recent news highlights dividend strength, branch expansion, and AI-driven growth initiatives.
The stock offers a compelling value proposition with a consensus price target of $258.92 (18.9% upside), supported by loan growth and efficiency gains. Key risks include interest rate sensitivity and macroeconomic pressures. Analyst sentiment is mixed, with 31% buy ratings but a majority hold stance, reflecting cautious optimism amid a challenging rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
